

MOMENTA PHARMACEUTICALS INC  
Form 8-K/A  
November 05, 2010

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K/A**

(Amendment No. 1)

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **October 19, 2010**

**Momenta Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-50797**  
(Commission File Number)

**04-3561634**  
(IRS Employer  
Identification No.)

**675 West Kendall Street, Cambridge, MA**  
(Address of Principal Executive Offices)

**02142**  
(Zip Code)

**(617) 491-9700**

(Registrant's telephone number, including area code)

Edgar Filing: MOMENTA PHARMACEUTICALS INC - Form 8-K/A

**Not applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

Momenta Pharmaceuticals, Inc. (the Company ) hereby amends its Current Report on Form 8-K filed on October 25, 2010 (the Original Form 8-K ) to provide information that was not determined or available at the time of filing the Original Form 8-K. The Original Form 8-K was filed to report the intention of Steven B. Brugger to resign as the Company s Chief Operating Officer.

(b) As previously disclosed, on October 19, 2010, Steven B. Brugger notified the Company of his intention to resign as the Company s Chief Operating Officer in order to join a privately held biotechnology company as its Chief Executive Officer. The effective date of Mr. Brugger s resignation is November 5, 2010. Mr. Brugger will serve as a consultant to the Company for a period following his resignation.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**MOMENTA PHARMACEUTICALS, INC.**

Date: November 5, 2010

By: /s/ RICHARD P. SHEA  
Richard P. Shea  
Senior Vice President and Chief Financial Officer  
(Principal Financial Officer)